Oncology News | pharmaphorum

News

Merck puts big bucks behind ADC alliance with China's Kelun

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech tha

News

EU approves AZ's Imfinzi plus chemo for advanced biliary tra...

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the

News

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking

News

Gilead's Kite takes control of CAR-T partner Tmunity

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit.

News

NICE expands breast cancer patient population eligible for E...

AstraZeneca and Daiichi Sankyo's Enhertu will become an option for hundreds more people with breast cancer in England and Wales, thanks to new guidance from NICE that will make it available

News

Atara claims first world approval for off-the-shelf T-cell t...

Atara Biotherapeutics has become the first biotech to win regulatory approval for a T-cell therapy based on donated cells, rather than relying on cells harvested from patients and processed

Merck puts big bucks behind ADC alliance with China's Kelun

EU approves AZ's Imfinzi plus chemo for advanced biliary tra...

Jazz opts in to Zymeworks HER2 drug for $325m upfront

Gilead's Kite takes control of CAR-T partner Tmunity

NICE expands breast cancer patient population eligible for E...

Atara claims first world approval for off-the-shelf T-cell t...

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks